A recent study from Queen’s University Belfast has brought attention to a concerning increase in mortality risk among dementia patients prescribed specific antidepressants and anti-anxiety medications. Highlighting these findings on BBC Morning Live, Dr. Oscar Duke stressed the importance of understanding the implications without causing undue alarm.
The study analyzed data from nearly 29,000 dementia patients in Northern Ireland over nine years (2012-2020), revealing that antidepressants such as Sertraline, Citalopram, and Fluoxetine were associated with an approximate 8% increase in mortality over ten years. More strikingly, the use of anti-anxiety drugs like diazepam and lorazepam correlated with a 26% increase in mortality.
Dr. Duke emphasized that these medications, commonly prescribed to manage symptoms like anxiety, depression, and distress in dementia patients, may carry risks tied to their sedative effects. Patients using these drugs could face heightened dangers such as increased confusion, greater fall risk, and subsequent injuries like fractures, which can significantly reduce life expectancy.
READ MORE: Concerns Raised Over Late-Night Techno Festival at Cotswold Airport
READ MORE: GP Explains NHS 9-Minute Rule and What Happens If You’re Late to Your Appointment
“It’s essential not to panic but to have open conversations with healthcare providers about whether these medications are necessary and beneficial,” Dr. Duke advised. As dementia prevalence rises—currently affecting nearly one million people in the UK and over 55 million globally—careful consideration of treatment regimens remains critical.
Dr. Catherine Sinnamon, lead author and postgraduate research student at Queen’s University Belfast, explained the study’s aim to ensure dementia patients receive appropriate care: “Given dementia’s status as a leading cause of death worldwide and the lack of effective treatments, improving quality of life through careful medication management is vital.”
The research underscores the importance of regular medication reviews by doctors and pharmacists to balance symptom management with safety. Dr. Heather Barry, principal investigator, called for judicious prescribing and ongoing assessment to mitigate risks associated with these common medications.
Supported by the Honest Broker Service and funded by the Northern Ireland Department of Health, this study contributes valuable insights to dementia care strategies, highlighting a delicate balance between managing mental health symptoms and preserving life expectancy.